GCS

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, Research, A4, GC, Congenital adrenal hyperplasia, Administration, PCOS, P-value, GCS, Patient, Cash, Șaeș, Spruce, Outline, CAH, Clinical trial, Safety, Hyperandrogenism, Polycystic ovary syndrome, ULN, Research and development, Food, FDA, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
  • “We are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences.
  • Non-cash stock-based compensation expense for the year ended December 31, 2023 was $4.6 million compared to $3.6 million in 2022.
  • Net Loss: Net loss for the year ended December 31, 2023 was $47.9 million compared to $46.2 million in 2022.

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, GC, Obesity, Endocrinology, Clinical professor, Associate, Risk, Patient, GCS, Mayo Clinic, Androgen, Șaeș, CAH, Endocrine system, Safety, Workforce, Medical director, ACTH, Pharmaceutical industry

Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.

Key Points: 
  • Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.
  • 70% of patients with elevated baseline A4 values (16 of 23 patients) demonstrated an A4 reduction at week 4.
  • “The CAHptain-205 study results demonstrate safety and tolerability in pediatric CAH patients with weight-adjusted tildacerfont doses up to 200mg daily.
  • An archived copy of the call will be available on the events section of the company’s investor relations website for approximately 90 days.

GameChange Solar Validates Performance Enhancement Software Features of its Genius Tracker™ Solar Trackers

Retrieved on: 
Wednesday, March 27, 2024
Wind, Safety, GCS, Genius, Plant, Research, Forecasting, Algorithm, Weather, Renewable energy

NORWALK, Conn., March 27, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of advanced, cost-effective solar tracking solutions for ground-mounted photovoltaic (PV) plants, announces third-party validation of certain performance enhancement features of its Genius Tracker™ solar trackers. Enertis, an independent research and analysis firm, has conducted a comprehensive analysis of the company's proprietary Genius Tracker™ control logic algorithms, confirming significant gains in the tracker's energy production beyond the industry standard gains from solar trackers.

Key Points: 
  • Enertis confirms performance gains from PowerBoost™, SmartStow, and WeatherSmart™
    NORWALK, Conn., March 27, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of advanced, cost-effective solar tracking solutions for ground-mounted photovoltaic (PV) plants, announces third-party validation of certain performance enhancement features of its Genius Tracker™ solar trackers.
  • Enertis, an independent research and analysis firm, has conducted a comprehensive analysis of the company's proprietary Genius Tracker™ control logic algorithms, confirming significant gains in the tracker's energy production beyond the industry standard gains from solar trackers.
  • The report includes models that estimate power production from three cutting-edge algorithms developed by GameChange Solar.
  • For more information about GameChange Solar and its innovative solar energy solutions, please visit www.gamechangesolar.com .

GameChange Solar Validates Performance Enhancement Software Features of its Genius Tracker™ Solar Trackers

Retrieved on: 
Wednesday, March 27, 2024
Wind, Safety, GCS, Genius, Plant, Research, Forecasting, Algorithm, Weather, Renewable energy

NORWALK, Conn., March 27, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of advanced, cost-effective solar tracking solutions for ground-mounted photovoltaic (PV) plants, announces third-party validation of certain performance enhancement features of its Genius Tracker™ solar trackers. Enertis, an independent research and analysis firm, has conducted a comprehensive analysis of the company's proprietary Genius Tracker™ control logic algorithms, confirming significant gains in the tracker's energy production beyond the industry standard gains from solar trackers.

Key Points: 
  • Enertis confirms performance gains from PowerBoost™, SmartStow, and WeatherSmart™
    NORWALK, Conn., March 27, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of advanced, cost-effective solar tracking solutions for ground-mounted photovoltaic (PV) plants, announces third-party validation of certain performance enhancement features of its Genius Tracker™ solar trackers.
  • Enertis, an independent research and analysis firm, has conducted a comprehensive analysis of the company's proprietary Genius Tracker™ control logic algorithms, confirming significant gains in the tracker's energy production beyond the industry standard gains from solar trackers.
  • The report includes models that estimate power production from three cutting-edge algorithms developed by GameChange Solar.
  • For more information about GameChange Solar and its innovative solar energy solutions, please visit www.gamechangesolar.com .

Ivy Rehab and Hospital for Special Surgery's Orthopedic Residency Program Earns ABPTRFE Accreditation

Retrieved on: 
Thursday, March 14, 2024
DPT, Organization, Growth, Therapy, Rehabilitation, Accreditation, Hospital, OCS, GCS, Health, HSS, Physical, Hedera, Nursing

WHITE PLAINS, N.Y., March 14, 2024 /PRNewswire/ -- Ivy Rehab proudly announces the accreditation of its Ivy Rehab HSS Orthopedic Residency program by the American Board of Physical Therapy Residency and Fellowship Education (ABPTRFE).

Key Points: 
  • WHITE PLAINS, N.Y., March 14, 2024 /PRNewswire/ -- Ivy Rehab proudly announces the accreditation of its Ivy Rehab HSS Orthopedic Residency program by the American Board of Physical Therapy Residency and Fellowship Education (ABPTRFE).
  • Christina Bentrewicz, PT, DPT, OCS, Ivy Rehab Director of Residency Programs, states, "The residency refines our clinicians' clinical reasoning and skills to provide high-quality, evidence-based care.
  • By combining resources, Ivy Rehab and HSS Rehab & Performance offer a unique residency experience for participants and prepare graduates to become leaders in the world of orthopedic physical therapy."
  • Ivy Rehab plans to pursue accreditation from the ABPTRFE for eligible residency programs, with the developing Ivy Rehab Pediatric Physical Therapy Residency program looking to seek accreditation next.

Calabrio Launches FedRAMP Authorized Offering, Calabrio GovSuite

Retrieved on: 
Tuesday, March 5, 2024
Software, Data Analytics, Machinery, Artificial Intelligence, Robotics, Professional Services, Technology, Manufacturing, Cloud, Political moderate, GCS, JAB, FedRAMP, Product management, Public sector, Interim, Software as a service, Organization, Platform as a service, Infrastructure as a service

Calabrio , the workforce performance company, announced today that it has launched Calabrio GovSuite, a Federal Risk and Authorization Management Program (FedRAMP®) Moderate authorized cloud contact center solution.

Key Points: 
  • Calabrio , the workforce performance company, announced today that it has launched Calabrio GovSuite, a Federal Risk and Authorization Management Program (FedRAMP®) Moderate authorized cloud contact center solution.
  • “For decades, our cloud solutions have enriched high-quality customer journeys and transformed how organizations manage contact center workforce performance,” said Raj Shankar, VP of Product Management, Calabrio.
  • “GovPoint Cloud Services is a cloud environment with a FedRAMP JAB Moderate authorization for IaaS, PaaS, and SaaS, and we are excited to have Calabrio GovSuite as part of our technology offering.”
    “This is a significant achievement for Calabrio,” said Joel Martins, Interim CEO and Chief Technology Officer, Calabrio.
  • “Security for our customers has always been a top priority for Calabrio and this FedRAMP milestone is another third-party validation attesting to our commitment to security.”

AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Fabry disease, PD, GCS, Drug development, Strong, Risk, Doctor of Philosophy, Safety, Therapy, Pharmacology, Pharmacokinetics, CNS, American College, Development, Patient, Pharmaceutical industry

AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.
  • “These results highlight the transformative potential of AL01211 as a best-in-class GCS inhibitor,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.
  • “Our Phase 1 study provided the critical safety and biomarker data to support our ongoing Phase 2 clinical trial in patients with Fabry Disease.
  • “In our trial, AL01211 demonstrated dose-dependent PK and PD effects with a clear correlation between AL01211 exposure and reduction in disease biomarkers.

Best Commercial Solar Panel Installation Companies (2024): Review of Industrial Solar Panels for Business Published By Better Business Advice

Retrieved on: 
Monday, February 26, 2024
Environment, Commercial Building & Real Estate, Construction & Property, Climate Change, Sustainability, Building Systems, Alternative Energy, Green Technology, Energy, Other Construction & Property, Farm, Green home, Electricity, Business, Solar energy, Carbon, GCS, Renewable energy

Better Business Advice shines a light on the best commercial solar panel installation companies entering 2024, spotlighting Green Home Systems and ShopSolarKits.com .

Key Points: 
  • Better Business Advice shines a light on the best commercial solar panel installation companies entering 2024, spotlighting Green Home Systems and ShopSolarKits.com .
  • ShopSolarKits.com : With a focus on affordability and transparency, ShopSolarKits.com is celebrated for making solar accessible to a broader audience.
  • Green Home Systems , traditionally known for residential solar solutions, is making waves through its commercial division, Green Commercial Systems (GCS).
  • Better Business Advice's review serves as an indispensable resource for businesses embarking on their solar energy journey in 2024.

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

GameChange Solar Validates 40-Year Maintenance-Free Design of Genius Tracker™ Drive System Through Accelerated Testing

Retrieved on: 
Wednesday, February 28, 2024
LCOE, IEC, GCS

NORWALK, Conn., Feb. 28, 2024 /PRNewswire/ -- GameChange Solar (GCS), a leading global supplier of solar tracking solutions for ground-mounted PV plants, announced that recent testing indicates that its Genius Tracker drive system has an expected 40-year design life with no expected maintenance requirements. The drive system was tested as part of the company's 40-year accelerated life cycle testing for the entire Genius Tracker structure. The accelerated lifecycle testing was performed in conformance with the Accelerated Mechanical Cycling section of the IEC 62817 standard. The results demonstrate the potential for decades of reliable performance, resulting in reduced maintenance costs and a lower Levelized Cost of Energy (LCOE) for our customers.

Key Points: 
  • The drive system was tested as part of the company's 40-year accelerated life cycle testing for the entire Genius Tracker structure.
  • The accelerated lifecycle testing was performed in conformance with the Accelerated Mechanical Cycling section of the IEC 62817 standard.
  • The key to the low-maintenance design of the Genius Tracker drive system lies in its linear actuator, which is self-contained and is expected not to require regreasing over the product design life.
  • "Testing of our Genius Tracker drive system indicates that its design significantly reduces, and possibly eliminates, the need for any greasing throughout its design life.